Evaluation of the blue formazan spot test for screening glucose 6 phosphate dehydrogenase deficiency.
Evaluation of the blue formazan spot test for screening glucose 6 phosphate dehydrogenase deficiency.
复制标题
评估蓝色甲臜斑点试验筛查葡萄糖 6 磷酸脱氢酶缺乏症的效果。
DOI：
--
复制
发表时间：
1999
影响因子：
2.1
通讯作者：
Corrons Jl
中科院分区：
文献类型：
--
作者：
A. Pujades;M. Lewis;Salvati Am;Shiro Miwa;Hisaichi Fujii;Rocío Zarza;Rodolfo Alvarez;E. Rull;Corrons Jl
迄今为止，已经报道了几种葡萄糖6磷酸脱氢酶（G6 PD）缺乏症的筛查试验，国际血液学标准化理事会（ICSH）提出了一种标准化的测试方法。在任何特定实验室中使用的筛选测试取决于许多因素，如成本，所需时间，温度，湿度和试剂的可用性。在这项研究中，直接比较了三种不同的G6 PD筛查方法。在71例（50例血液学正常志愿者，9例半合子G6 PD缺陷男性和12例杂合子缺陷女性）中，将蓝色甲瓒斑点试验（BFST）与常规高铁血红蛋白还原试验（HiRT）和ICSH推荐的荧光斑点试验（FST-ICSH）进行了比较。在所有情况下，用三种筛选试验获得的结果与酶活性测定相关。在半合子G6 PD缺陷男性中，所有病例均用三种方法检测到：BFST（4.7-6.64，对照：11.1-13.4），BMRT（所有9例评分+3）和FST（9例无荧光）。在杂合子G6 PD缺陷型女性中，两种方法检测到12例中的7例（BFST：8.71-11.75，对照：11.1-13.4; BMRT：7例评分+3），而FST-ICSH错过了所有12例呈现不同程度荧光的病例。尽管BMRT和BFST检测G6 PD缺陷携带者的灵敏度相同，但后者具有半定量而不仅仅是定性的优点。不幸的是，这里比较的三种筛查试验都不能检测出100%的G6 PD缺陷杂合子携带者。
Several screening tests for glucose 6 phosphate dehydrogenase (G6PD) deficiency have been reported thus far, and a standardized method of testing was proposed by the International Council for Standardization in Hematology (ICSH). The screening test used in any particular laboratory depends upon a number of factors such as cost, time required, temperature, humidity, and availability of reagents. In this study, a direct comparison between three different G6PD screening methods has been undertaken. In 71 cases (50 hematologically normal volunteers, 9 hemizygous G6PD-deficient males, and 12 heterozygous deficient females), the blue formazan spot test (BFST) was compared with the conventional methemoglobin reduction test (HiRT) and the ICSH-recommended fluorescent spot test (FST-ICSH). In all cases, the results obtained with the three screening tests were correlated with the enzyme activity assayed spectrophotometrically. In hemizygous G6PD-deficient males, all cases were equally detected with the three methods: BFST (4.7-6.64, controls: 11.1-13.4), BMRT (score +3 in all 9 cases), and FST (no fluorescence in 9 cases). In heterozygous G6PD-deficient females, two methods detected 7 out of 12 cases (BFST: 8.71-11.75, controls: 11.1-13.4; and BMRT: score +3 in 7 cases), whereas the FST-ICSH missed all 12 cases that presented a variable degree of fluorescence. Although the sensitivity for G6PD-deficient carrier detection is the same for the BMRT and the BFST, the latter has the advantage of being semiquantitative and not merely qualitative. Unfortunately, none of the three screening tests compared here allowed the detection of the 100% heterozygote carrier state of G6PD deficiency.